STA
ACRS icon

Summit Trail Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Summit Trail Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,831
Closed -$76K – 278
2018
Q2 		$76K Buy
+3,831
New +$70.8K 0.03% 252
2018
Q1 		– Sell
-2,375
Closed -$59K – 429
2017
Q4 		$59K Buy
+2,375
New +$57.8K 0.01% 773

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Summit Trail Advisors's ACRS Position: Q3 2018 in Review

Summit Trail Advisors sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 3,831 shares — an estimated $76K sold.

Summit Trail Advisors first reported a position in ACRS in Q4 2017 and held it in 2 quarters. The position peaked at $76K in Q2 2018. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

  • Summit Trail Advisors reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 3,831 Aclaris Therapeutics shares in Q3 2018, an estimated $76K.
  • Summit Trail Advisors first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Aclaris Therapeutics position peaked at $76K in Q2 2018.
  • 86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.